ClotCare: Blood Clots, Stroke, Heart Attack
Wednesday, October 18, 2017
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

New National Performance Measures Issue
Mandate to Reduce Incidence of Deep-Vein Thrombosis

Coalition to Prevent Deep-Vein Thrombosis
February, 2007

Washington, D.C., February 1, 2007 - The Coalition to Prevent Deep-Vein Thrombosis (DVT) today applauds new National Quality Forum (NQF) performance measures establishing nationwide preventive standards for Venous Thromboembolism (VTE), a condition that claims up to 300,000 American lives annually.

Venous Thromboembolism, which includes DVT and its complication, pulmonary embolism, (PE), is the most common preventable cause of hospital death. Each year, more lives are lost to complications of DVT than from breast cancer and AIDS combined. To address this issue, the two NQF endorsed publicly reported performance measures direct proper risk reduction and treatment practices for surgical patients.

"These new standards make DVT prophylaxis obligatory, not optional, which is a great step forward in protecting the health of our patients," said Coalition Steering Committee Member Samuel Z. Goldhaber, M.D., Professor of Medicine, Harvard Medical School; Staff Cardiologist, Brigham and Women's Hospital; Member, NQF Consensus Standards Steering Committee.

Surgical patients are known to be at higher risk for DVT, therefore the performance measures assess the number of surgical patients who are directed to receive preventive treatment for VTE, and the treatment received in the 48 hours surrounding surgery.

A vital step in the development of universal healthcare practices to reduce the risk of DVT and its complications, the performance measures lay the foundation for additional upcoming "National Consensus Standards for the Prevention and Care of VTE" currently being developed by the Joint Commission on Healthcare Accreditation (JCAHO) under contract with NQF.

Dr. Goldhaber stated, "The medical community recognizes that up two million Americans are affected each year by DVT. Once the JCAHO and NQF standards are fully integrated into the daily practice of healthcare systems across the country, we can be assured that the healthcare community is doing its best to address this potentially fatal condition."

"The members of the Coalition to Prevent DVT have worked tirelessly to increase public awareness of DVT and we welcome the NQF measures as a vital step to help other individuals hopefully avoid the experience that my family has had with DVT," said Coalition to Prevent DVT National Patient Spokesperson Melanie Bloom, widow of NBC Correspondent David Bloom. Melanie Bloom is a member of the NQF VTE Consensus Standards Steering Committee.

About Deep-Vein Thrombosis and Pulmonary Embolism

DVT occurs when a thrombus (blood clot) forms in one of the large veins, usually in the lower limbs, leading to either partially or completely blocked circulation. If left untreated, this clot has the potential to move into the lungs and block circulation to this vital organ creating a life threatening condition - known as pulmonary embolism (PE) - requiring immediate medical attention. Up to 900,000 Americans are hospitalized each year for DVT and its primary complication, PE.

Certain individuals may be at increased risk for developing DVT; however, it can occur in almost anyone. Additional risk factors include, but are not limited to restricted mobility, cancer, certain heart or respiratory diseases, major surgery, such as hip or knee replacements, advanced age, oral contraceptives or hormone therapy.

It is important to consult your healthcare provider about the signs and symptoms associated with DVT. Click here to learn more about deep vein thrombosis (DVT).

The Coalition to Prevent Deep-Vein Thrombosis is funded by sanofi-aventis U.S., LLC.

About the Coalition to Prevent Deep-Vein Thrombosis

In February 2003, more than 60 organizations assembled at the Public Health Leadership Conference on Deep-Vein Thrombosis in Washington, D.C. to discuss the urgent need to make DVT a major U.S. public health priority. As a result of this meeting, which was co-hosted by the American Public Health Association and Centers for Disease Control and Prevention and funded by sanofi-aventis, participants agreed to establish a Coalition of organizations committed to educating the public and healthcare community about DVT. To date, 41 organizations have joined the Coalition to Prevent Deep-Vein Thrombosis, comprised of national thought leaders and representatives from key organizations, including the American College of Chest Physicians, the American Public Health Association and the Society of Hospital Medicine.

The mission of the Coalition to Prevent Deep-Vein Thrombosis is:

To reduce the immediate and long-term dangers of deep-vein thrombosis (DVT) and pulmonary embolism (PE), which together comprise one of the nation’s leading causes of death. The Coalition will educate the public, healthcare professionals and policy-makers about risk factors, symptoms and signs associated with DVT, as well as identify evidence-based measures to prevent morbidity and mortality from DVT and PE.

The website of the Coalition to Prevent Deep-Vein Thrombosis is www.preventdvt.org.

Click here to read about DVT Awareness Month 2007.

Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

World Thrombosis Day - Oct. 13, 2017

Rivaroxaban or Warfarin in Stable Coronary Artery Disease – Should the COMPASS Study Lead Us Back to the Future?

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2014 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-495-4335
Send comments to webmaster@clotcare.org.
Wednesday, October 18, 2017